From COVID-19 vaccines to Moderna’s mRNA flu vaccine, using mRNA as medicine has shown promise. But before mRNA drugs can go beyond vaccines, researchers need to identify the right diseases to treat.
Articles on Moderna vaccine
Displaying 1 - 20 of 64 articles
After pushback, the agency reversed course and agreed to review Moderna’s application after all.
The new bivalent boosters against COVID-19 have failed to halt omicron infections. However, new technologies are being developed that pave a way forward.
Preventive and therapeutic vaccines both train the immune system to fight disease, but they are used in different ways.
The CDC’s endorsement of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
The FDA’s authorization of COVID-19 shots for children ages 6 months to 4 years will bring relief for millions of parents. Pending CDC endorsement, shots for this group will be available within days.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
New data on the second booster suggests the older you are, the more you need it.
Parents can now choose Moderna to vaccinate their children against COVID. So how effective is it, and how does it compare with Pfizer?
Some of the omicron variant’s unique properties – such as its ability to spread rapidly while causing milder COVID-19 infections – could usher in a new phase of the pandemic.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
There’s not enough evidence yet to support the AstraZeneca CEO’s statement. But it is theoretically plausible.
Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
When making the decision whether to vaccinate children aged five to 11 against COVID-19, regulators in Canada must rely on sound ethics as well as sound science.
Before the pandemic, the public perceived science as infallible and inaccessible. But the opening up of research to the general public has changed that perception.
Thanks to the collaborative efforts of governments, funding agencies, academia, biotech and pharmaceutical companies, large-scale manufacturing of mRNA drug products is becoming a reality.
A medical student answers questions he gets asked at a COVID-19 vaccine clinic: Efficacy versus real-world effectiveness, immune response and how the mRNA vaccines compare to vaccines already in wide use.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Instructor of Human Immunology, Emory University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Law, Villanova University
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Professor, Biology, York University, Canada
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Professor of Microbiology, School of Medicine, University of Washington
-
Clinician-Scientist Trainee, Faculty of Medicine & Dentistry and Faculty of Science, University of Alberta
-
Adjunct Professor of Epidemiology, University of Texas Health Science Center at Houston
-
Clinical Professor of Pharmacy Practice, University of Connecticut
-
Group Leader: Next-generation Vaccines, Antiviral Gene Therapy Research Unit, University of the Witwatersrand